Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of BW-50218 in Healthy Participants
Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.
Summary
Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-02-25
Completion Date
2027-06-30
Last Updated
2026-03-05
Healthy Volunteers
Yes
Conditions
Interventions
BW-50218 Injection
Solution for injection
Saline (0.9% NaCl)
Solution for injection
Locations (2)
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, Australia
Linear Early Fhase Limited
Nedlands, Western Australia, Australia